Psoriasis Series

Safety of Biologics: The Risk of Infection and Malignancy With Biologic Therapy

Free

Includes:
Lectures: 0
Credits: 0.75
Supported by independent educational grants from Ortho Dermatologics and Sun Pharmaceutical Industries, Inc.

About this course


General
Skill level: all levels
Estimated time to complete activity: 45 min
Release date: October 08, 2018
Expiration date: October 07, 2019

Languages
English

Accreditations
American Nurses Credentialing Center(ANCC), American Medical Association(AMA)

Description

This activity is part of a 14-course series designed to equip licensed practitioners from medical, nursing, and related disciplines with a multidisciplinary approach to managing patients with psoriasis.

12. Safety of Biologics

One-third of adult psoriasis patients develop symptoms starting in childhood. Learn about the diagnostic challenges and management of childhood psoriasis.

Educational Objectives

After completing this activity, participants will able to:

  • Discuss the common safety precaution for biologics based on class of medications
  • Review the data from clinical trials and registry studies

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty Reported Financial Relationship
Jashin Wu, MD Research Funding: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Regeneron

Instructor

Jashin Wu, MD

Contact Information

This activity is jointly provided by SynAptiv and Dermeda

Questions about CE accreditation or CE certificates related to this course, please contact us via email at yourcesource@synaptiv.org.

Copyright © 2018 Dermveda. All rights reserved. This material may not be reproduced, displayed, modified or distributed without the express prior written permission of the copyright holder.

Free

Includes:
Lectures: 0
Credits: 0.75